July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Long-term visual and anatomical outcomes in treatment naïve neovascular age-related macular degeneration (nAMD) patients treated with anti-VEGF agents
Author Affiliations & Notes
  • Saleema A. Kherani
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States
  • Roomasa Channa
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States
  • Rimsha Shaukat
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States
  • Olukemi Adeyemo
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States
  • Mustafa Iftikhar
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States
  • Adrienne Scott
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States
  • Akrit Sodhi
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States
  • James T Handa
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States
  • Ingrid Zimmer-Galler
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States
  • Adam Wenick
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States
  • Sharon D Solomon
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States
  • Mira Sachdeva
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States
  • Catherine B Meyerle
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States
  • Peter A Campochiaro
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Saleema Kherani, None; Roomasa Channa, None; Rimsha Shaukat, None; Olukemi Adeyemo, None; Mustafa Iftikhar, None; Adrienne Scott, None; Akrit Sodhi, None; James Handa, None; Ingrid Zimmer-Galler, None; Adam Wenick, None; Sharon Solomon, None; Mira Sachdeva, None; Catherine Meyerle, None; Peter Campochiaro, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 825. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Saleema A. Kherani, Roomasa Channa, Rimsha Shaukat, Olukemi Adeyemo, Mustafa Iftikhar, Adrienne Scott, Akrit Sodhi, James T Handa, Ingrid Zimmer-Galler, Adam Wenick, Sharon D Solomon, Mira Sachdeva, Catherine B Meyerle, Peter A Campochiaro; Long-term visual and anatomical outcomes in treatment naïve neovascular age-related macular degeneration (nAMD) patients treated with anti-VEGF agents. Invest. Ophthalmol. Vis. Sci. 2018;59(9):825.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess long-term visual and anatomic outcomes in treatment naïve nAMD patients treated with intravitreal injections of anti-VEGF agents.

Methods : Screening of nAMD patients seen by a co-author between January and December 2014 identified 274 eyes of 233 patients with ≥6 month follow up; out of which 136 eyes of 120 patients had subfoveal (SF) choroidal neovascularization (CNV) treated with injections of an anti-VEGF agent. Eyes with geographic atrophy, subretinal (SR) fibrosis, and large SR hemorrhage were excluded.

Results : Mean follow-up duration was 3.6±0.3 (0.6 to 5.4) years. Baseline visual acuity (VA) was ≥20/40, 20/50-20/160, or ≤20/200 in 51.5%, 43.4%, 5.1% patients. The percentage of patients with final VA ≥20/40, 20/50-20/160, or ≤20/200 was 64.0, 26.5, 9.5. Change from baseline VA at final visit was a gain ≥6, ≥3, ≥2, ≥1 lines in 1 (0.7%), 21 (15.4%), 39 (28.7%), 58 (42.6%), no change in 31 (22.8%), and loss of ≥1, ≥2, ≥3, ≥6 lines in 47 (34.6%), 25 (18.4%), 19 (14.0%), 12 (8.8%) patients. Mean baseline and final central subfield thickness (CST) was 321.0±6.8µm and 251.1±6.8µm respectively, with a mean decrease of -69.9±7.5µm at final visit. The rate of anti-VEGF injections per year was 5.7±0.3. Final VA was significantly correlated with baseline VA (r=0.559, p<0.001), rate of injection per year (r=0.219, p<0.01), and change in CST (r=0.221, p<0.01).

At final visit, 26.5% eyes had intraretinal (IR) fluid, 27.9% had SR fluid and 12.5% had both IR and SR fluid. Seven (5.1%) eyes had outer retinal tubulations. Height of pigment epithelial detachment increased in 34.6% and decreased in 44.9% at final visit. Four (0.3%) eyes had non-fibrotic SR hyper-reflective material in the fovea, 10 (7.4%) eyes had SF fibrosis, and 22 (16.2%) eyes had SF atrophy at final visit. Atrophy at final visit was negatively correlated with rate of anti-VEGF injections per year (r= -0.190, p=0.027). A significant correlation was noted between baseline VA with atrophy (r= -0.194, p=0.023) and SR fibrosis (r= -0.235, p=0.006) at final visit.

Conclusions : In nAMD patients, long-term frequent anti-VEGF injections provide good visual and anatomic outcomes. There is an association of good outcomes with better baseline VA, higher change in CST, and higher rate of anti-VEGF injections per year where fewer patients receiving frequent anti-VEGF developed atrophy.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×